STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

[SCHEDULE 13G] Monte Rosa Therapeutics, Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G
Rhea-AI Filing Summary

Monte Rosa Therapeutics, Inc. received a joint Schedule 13G filing showing that Dimension Capital I, L.P. and affiliated reporting persons collectively beneficially hold 4,757,563 shares of the issuer's common stock, representing 7.7% of the class. The filing lists the reporting persons as Dimension Management, L.P., Dimension Capital I GP, LLC, Dimension Management GP, LLC, Dimension Capital I, L.P. and individuals Adam Goulburn, Zavain Dar, and Nan Li. The cover information states the ownership percentages are calculated using 61,759,350 outstanding shares reported by the issuer as of August 1, 2025. The reporting persons disclose shared voting and dispositive power over the disclosed shares and certify the shares were not acquired to change control of the company.

Positive
  • 4,757,563 shares disclosed provides transparent ownership detail
  • 7.7% stake exceeds 5% threshold, triggering public disclosure
  • Ownership calculation tied to 61,759,350 outstanding shares as of August 1, 2025
Negative
  • None.

Insights

TL;DR: A passive investor group reports a 7.7% beneficial stake in Monte Rosa (GLUE).

The Schedule 13G shows Dimension Capital I, L.P. directly holds 4,757,563 shares, with shared voting and dispositive power allocated across affiliated entities and three named individuals.

This filing is structured as a passive Schedule 13G and includes a certification that the holdings were not acquired to influence control; that classification is relevant to how investors interpret intent and regulatory obligations.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Adam Goulburn
Signature:/s/ Adam Goulburn
Name/Title:Adam Goulburn
Date:10/03/2025
Zavain Dar
Signature:/s/ Zavain Dar
Name/Title:Zavain Dar
Date:10/03/2025
Nan Li
Signature:/s/ Nan Li
Name/Title:Nan Li
Date:10/03/2025
Dimension Management, L.P.
Signature:/s/ Adam Goulburn
Name/Title:By: Dimension Management GP, LLC, its general partne; By: Adam Goulburn, Member
Date:10/03/2025
Dimension Capital I GP, LLC
Signature:/s/ Adam Goulburn
Name/Title:Adam Goulburn, Member
Date:10/03/2025
Dimension Management GP, LLC
Signature:/s/ Adam Goulburn
Name/Title:Adam Goulburn, Member
Date:10/03/2025
Dimension Capital I, L.P.
Signature:/s/ Adam Goulburn
Name/Title:By: Dimension Capital I GP, LP, its general partner; By: Adam Goulburn, Member
Date:10/03/2025
Exhibit Information

99.1 Joint Filing Agreement

FAQ

What stake in Monte Rosa (GLUE) is disclosed in this Schedule 13G?

The filing discloses a beneficial ownership of 4,757,563 shares, equal to 7.7% of outstanding common stock.

Who are the reporting parties named on the filing for GLUE?

Reporting persons include Dimension Capital I, L.P., Dimension Management, L.P., Dimension Capital I GP, LLC, Dimension Management GP, LLC, and individuals Adam Goulburn, Zavain Dar, and Nan Li.

What voting or dispositive power is reported?

The filing reports 0 sole voting/dispositive power and 4,757,563 shared voting and dispositive power for each reporting person.

On what share count is the percentage ownership based?

The 7.7% figure is based on 61,759,350 outstanding shares reported by the issuer as of August 1, 2025.

Does the filing indicate an intent to influence control of Monte Rosa?

The signatories certify the securities were not acquired and are not held for the purpose of changing or influencing control of the issuer.
Monte Rosa Therapeutics, Inc.

NASDAQ:GLUE

GLUE Rankings

GLUE Latest News

GLUE Latest SEC Filings

GLUE Stock Data

925.97M
64.59M
0.73%
100.42%
13.34%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
BOSTON